Market Snapshot

S&P Futures
4,403.25
Dow Futures
34,956.00
NASDAQ Futures
15,093.50

What Happened Last Session To Make Enzolytics (ENZC) Stock Drop?

Related Topics

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

After dropping -2.38% in the last session, Enzolytics Inc (OTCPINK: ENZC) closed the last session at $0.2010, bringing its market cap to $562.39M. Enzolytics stock recently traded 42.22M shares, higher than the average daily volume of 41.93M. In addition, the shares have traded between $0.1821 and $0.2289. There are 2.80 billion outstanding shares compared to a float of 1.88 billion.

As measured by performance, ENZC stock performed -27.44% last week and 57.40% last month. While the quarterly performance fell by 33.07 percent, the annual performance improved by 51.85 percent with a 215.05% six-month performance. ENZC stock prices ranged from $0.0002 – $0.9580 in the past 52 weeks. Despite announcing progress in clinical trials, ENZC stock dropped.

What was the purpose of those clinical trials?

Enzolytics is a pharmaceutical company dedicated to the development and commercialization of proprietary proteins and monoclonal antibodies to treat disease caused by debilitating infectious agents. A number of therapeutics are being developed by ENZC for the treatment of infectious diseases. Among the ENZC’s patented and clinically tested compounds, ITV-1 (Immune Therapeutic Vaccine-1) contains l-inactivated pepsin fraction (IPF) that has been shown effective in treating HIV/AIDS.

A strategy by Enzolytics to advance its previously tested anti-HIV therapeutic ITV-1 to clinical trials and widespread distribution in Europe has been finalized.

  • ENZC will achieve a significant milestone for both human health and profitability when these steps are completed for its anti-HIV therapy.
  • An anti-HIV therapeutic developed by ENZC earlier made progress toward Bulgarian Drug Agency (BDA) certification, however that process was interrupted before it was completed.
  • A significant number of positive results from clinical trials were nevertheless documented during that period.
  • ENZC has no doubt that the clinical trials under the European Medicines Agency (EMA) will similarly succeed as a result of these positive results

How ENZC will go through it?

International Medical Partners Ltd. (IMPL) was formed by Enzolytics (ENZC) and European-based partners. IMPL is owned equally by ENZC and its partners and has the licenses to distribute the ITV-1 therapeutic in the 27 European countries covered by the European Medical Agency including Russia and its ex-Soviet states.

For the initial production of ITV-1, ENZC engages Danhson Ltd., a Contract Manufacturing Company (CMO) for use in preparing the Best Methods Report for future production and clinical trial documentation.

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Latest Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam